Omeros (NASDAQ:OMER) Receives “Buy” Rating from D. Boral Capital

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They currently have a $36.00 target price on the biopharmaceutical company’s stock. D. Boral Capital’s price objective would suggest a potential upside of 200.88% from the stock’s current price.

A number of other brokerages have also recently commented on OMER. Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a research note on Thursday. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. Wall Street Zen downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. WBB Securities reissued a “strong-buy” rating and set a $45.00 target price on shares of Omeros in a research report on Wednesday, October 15th. Finally, HC Wainwright upped their target price on shares of Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Omeros currently has an average rating of “Moderate Buy” and a consensus target price of $40.33.

Omeros Stock Performance

Omeros stock traded up $0.44 during trading on Tuesday, hitting $11.97. The company’s stock had a trading volume of 445,659 shares, compared to its average volume of 2,807,493. The stock’s fifty day moving average is $11.72 and its 200 day moving average is $7.38. Omeros has a 1-year low of $2.95 and a 1-year high of $17.65. The stock has a market capitalization of $848.32 million, a price-to-earnings ratio of -5.91 and a beta of 2.38.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.39. On average, research analysts anticipate that Omeros will post -3.09 EPS for the current fiscal year.

Insider Activity at Omeros

In other news, CAO David J. Borges sold 30,000 shares of the stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 12.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Farther Finance Advisors LLC boosted its stake in shares of Omeros by 16.5% during the 4th quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 1,004 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Omeros by 9.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 31,728 shares of the biopharmaceutical company’s stock worth $545,000 after purchasing an additional 2,631 shares during the period. JPMorgan Chase & Co. raised its stake in Omeros by 1,201.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock valued at $1,706,000 after purchasing an additional 384,168 shares during the period. Millennium Management LLC boosted its position in shares of Omeros by 49.1% in the third quarter. Millennium Management LLC now owns 401,814 shares of the biopharmaceutical company’s stock worth $1,647,000 after buying an additional 132,393 shares during the period. Finally, Brevan Howard Capital Management LP lifted its stake in Omeros by 22.9% in the 3rd quarter. Brevan Howard Capital Management LP now owns 129,393 shares of the biopharmaceutical company’s stock worth $531,000 after acquiring an additional 24,094 shares in the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.